TVGN Tevogen Bio Holdings Inc.
FY2024 10-K
Tevogen Bio Holdings Inc. (TVGN) filed its fiscal year 2024 10-K annual report with the SEC on Apr 2, 2025. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2024 10-K
Business Overview
- • Core business: Clinical-stage immunotherapy developing off-the-shelf, precision allogeneic CD8+ T cell therapies for infectious diseases, cancers, and other disorders
- • New emphasis on TVGN 489 for COVID-19 and Long COVID, with Phase 1 proof-of-concept trial completed Jan 2023 and pivotal trial planned for B cell malignancy patients
Management Discussion & Analysis
- • Revenue $0, no product sales, consistent with prior year; no expected revenue until product approval and commercialization
- • Net loss $13.7M in 2024 vs $60.5M in 2023; loss from operations $53.6M in 2024 vs $8.8M; operating expenses rose to $53.6M from $8.8M
Risk Factors
- • Regulatory risk: FDA's evolving framework on allogeneic T cell therapy and AI use, with draft guidance increasing compliance costs and potential delays
- • Geopolitical/macro risk: Reliance on $8.0 million grant funding expected Q2 2025 from KRHP LLC critical for liquidity amid no secured additional financing
Financial SummaryXBRL
Net Income
-$14M
ROE
205.7%
Total Assets
$3M
EPS (Diluted)
$-0.07
Operating Cash Flow
-$12M
Source: XBRL data from Tevogen Bio Holdings Inc. FY2024 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Tevogen Bio Holdings Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.